Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

neoplasm of uncertain malignant potential

Known as: Neoplasm of Borderline Malignancy, Neoplasm of Low Malignant Potential, NEOPLASMS OF UNCERTAIN BEHAVIOR 
A neoplasm displaying morphologic, phenotypic, or genotypic characteristics that are clearly not benign but do not permit the establishment of a… Expand
National Institutes of Health

Related topics

Related topics

6 relations
LarynxNeoplastic CellNeurofibromatosesNeurofibromatosis 1
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.
Metabolites are the end products of cellular regulatory processes, and their levels can be regarded as the ultimate response of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
OBJECTIVE Mutations of BRAF, a downstream mediator of K-RAS, have been described in serous borderline tumors of the ovary. Data… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With…
The infrequent association of serous borderline tumors (SBTs) with invasive serous carcinoma has led to the view that SBTs are… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors): Outcome-Based Study of 276 Patients With Long-Term (≥5-Year) Follow-Up
The natural history, classification, and nomenclature of ovarian serous tumors of low malignant potential (S-LMP) (serous tumors… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Molecular genetic changes that are associated with the initiating stage of tumor development are important in tumorigenesis… Expand
  • figure 1
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Mucinous Tumors of the Ovary: A Clinicopathologic Analysis of 75 Borderline Tumors (of Intestinal Type) and Carcinomas
With the exception of benign cystadenomas, mucinous ovarian tumors are rare and heterogeneous neoplasms. They have been… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study.
PURPOSE Borderline tumors account for 10% to 20% of epithelial ovarian tumors, and their prognosis is outstanding; nevertheless… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Mucinous Tumors of the Ovary: A Clinicopathologic Study of 196 Borderline Tumors (of Intestinal Type) and Carcinomas, Including an Evaluation of 11 Cases With `Pseudomyxoma Peritonei'
  • K. Lee, R. Scully
  • The American journal of surgical pathology
  • 2000
    • Corpus ID: 36588302
Mucinous ovarian neoplasms other than cystadenomas and adenofibromas have been classified as either borderline tumors or… Expand
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
Poor outcome in serous borderline tumors (SBT) of the ovary is limited to patients with advanced stage disease. This study was… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE